ClinicalTrials.gg
CompletedNCT03226444Updated Jan 22, 2020

Lacripep™ in Subjects With Dry Eye Associated With Primary Sjögren's Syndrome

A Phase 1/2 interventional study of 0.005% Lacripep and 0.01% Lacripep in Primary Sjögren Syndrome and Dry Eye, sponsored by TearSolutions, Inc.. Completed at 35 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-01-22.

Sponsored by TearSolutions, Inc. · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Dec 2019, 6 years 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
204
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 544 studies in Dry Eye Syndromes with a site in United States — 52 open to participants now, 63 under way, 3 of them phase 3. Dry Eye Syndromes · United States.

Enrollment
103rd of 473
204 · median 60
Started
2017
with 15 others
Phase 1/2
17 of 544
none open now
Registered
242nd of 544
by date

Among the 544 studies in Dry Eye Syndromes with a site in United States, this one is the 103rd largest by enrollment of the 473 interventional ones that give a count, is one of 16 that started in 2017, is one of 17 in phase 1/2, and was the 242nd registered.

Dry Eye Syndromes

1,370 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

52 of the 544 studies in Dry Eye Syndromes with a site in United States are open now. Recruiting first, the newest first:

47 more — sign in →

All 52 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 117 Dry Eye Syndromes studies recruiting now, 74 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 544 studies in Dry Eye Syndromes with a site in United States, or all of them as a file.
02

Study summary

The objective of this study is to evaluate the efficacy and safety of two strengths of Lacripep™ ophthalmic solution versus placebo administered three times daily for four weeks in subjects with a diagnosis of Dry Eye associated with documented Primary Sjögren's Syndrome

Read the detailed description

This is a multi-center, randomized, placebo-controlled, double-masked, parallel-group study. Subjects will be randomized into three treatment groups: 0.005%, or 0.01% Lacripep™, or placebo in a 1:1:1 ratio.

03

Conditions studied

  • Primary Sjögren Syndrome
  • Dry Eye

Keywords

  • Dry Eye
  • Primary Sjogren's Syndrome
  • Sjogren's Syndrome
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects who meet the following criteria will be selected:

  1. Subjects who are age 18 years of age or older at the time of obtaining .
  2. Subjects with a documented prior history or current diagnosis of Primary Sjögren's Syndrome according the American-European Consensus Group Sjögren's Syndrome Criteria (Appendix 4; must meet either 4 out of 6 total criteria OR 3 out of 4 signs). Note: Subjects who are on systemic (oral) therapy for the treatment of Sjögren's Syndrome must be on stable systemic treatment defined as the same treatment for the immediately prior 90 days.
  3. Subjects with a history of dry eye-related ocular symptoms, and who have self-reported use of over the counter ocular wetting agents within the last 120 days.
  4. Subjects who meet the following criteria at both screening and Visit 2 (Randomization/Baseline) examinations:

    1. FCS total score ≥ 4 and \< 15 in the NEI/Industry Workshop scale, (Appendix 6)
    2. Symptom Severity score of ≥ 40 using the SANDE questionnaire (Appendix 3)
    3. Anesthetized Schirmer test score ≤ 5 mm wetting/5 min
    4. LGCS total score ≥ 5 using the NEI/Industry Workshop scale (where 0=no staining) Note: Subjects must meet all 4 criteria and eligible scores for FCS, Anesthetized Schirmer and LGCS must be in at least one eye and it must be in the same eye at the time of the visit.

Exclusion criteria

Exclusion Criteria:

Subjects meeting any of the following criteria at the Visit 1 (Screening) or Visit 2 (Randomization/Baseline) visits will be excluded:

  1. Subjects with any active infectious ocular condition.
  2. Subjects who are monocular or have a BCVA, using corrective lenses if necessary, of +1.0 logMAR or worse as assessed by Early Treatment Diabetic Retinopathy Study (ETDRS).
  3. Subjects with ocular inflammatory conditions (e.g., conjunctivitis, keratitis, anterior blepharitis, etc.) not related to dry eye syndrome.
  4. Subjects with clinical evidence of cicatricial ocular surface disease, such as cicatricial ocular pemphigoid or Stevens Johnson syndrome.
  5. Subjects who cannot suspend the use of any topical eye medications (including topical cyclosporine) other than the product during the run-in and the study treatment phase.
  6. Subjects who have used Restasis® (topical ophthalmic cyclosporine) or Xiidra® (topical ophthalmic lifitegrast) within 14 days prior to Visit 1.
  7. Subjects who in the study eye have fluorescein corneal staining (FCS) Total Score = 15 or a Score = 3 in the superior region per the NEI/Industry Workshop scale or subjects who have FCS with diffuse confluent staining, filaments or frank epithelial defects.
  8. Subjects who have active or have had an outbreak of herpetic keratitis within 365 days of Visit 1 or subjects who are on chronic oral antivirals for ocular herpetic disease.
  9. Subjects who cannot suspend the use of and abstain from contact lens use from the Screening Visit (Visit 1) to the end of the study (Visit 5).
  10. Subjects who have a history of collagen vascular disease, auto immune disease or rheumatic disease other than Primary Sjögren's Syndrome (e.g., Lupus, Rheumatoid Arthritis, etc.).
  11. Subjects who have a history of or current Anterior Membrane Dystrophy.
  12. Subjects who have had a corneal transplant or similar corneal surgery (DALK, DSEK, DMEK, etc.).
  13. Subjects who have used or anticipate use of amiodarone.
  14. Subjects who within 30 days prior to Visit 1 alter the dose or anticipate alterations to the dose of the following: tetracyclines, Omega 3's or 6's.
  15. Subjects who within 60 days prior to Visit 1 and for the duration of the study alter the dose or anticipate alterations to the dose of the following: anticholinergics, antidepressants, oral , isotretinoin, oral systemic , oral systemic agents.
  16. Subjects who within 30 days prior to Visit 1 and for the duration of the study use topical ocular antihistamines, ocular, inhaled or intranasal corticosteroids, topical or oral mast cell stabilizers, oral antihistamines, topical or nasal vasoconstrictors, topical ocular NSAIDs, topical ocular antibiotics or serum tears.
  17. Subjects who in the study eye have had cauterization of the punctum or alterations to (insertion or removal) punctal plug(s) within the past 14 days prior to Visit 1. Note: If a punctal plug in place at Visit 2 (Randomization/Baseline) and it is dislodged, the plug should be replaced as soon as possible.
  18. Subjects who, in the study eye, have had corneal refractive surgery (LASIK, PRK, RK).
  19. Subjects who in the study eye, have a history of any operative procedure on the ocular surface or eyelids within 365 days prior to Visit 1 or with a history of intraocular surgery within 90 days prior to Visit 1.
  20. Subjects who are pregnant or suspected to be pregnant and subjects who are breastfeeding or intend to breastfeed. Female subjects of are required to have a negative urine pregnancy test at screening, and must agree to use an acceptable method of contraception from the time of signing until the end of study visit. Medically acceptable contraception methods include intrauterine device; barrier methods such as diaphragm, condom, cap or sponge, used with a spermicide; or hormonal contraception.
  21. Subjects with any physical or mental impairment that would preclude participation and the ability to give informed consent.
  22. Subjects who have participated in a device or Investigational drug study or clinical trial within 30 days of Visit 1. Participation in another during this study is excluded for the duration of this study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
204 participants (actual)

Study arms

  • Experimental
    0.005% Lacripep

    0.005% Lacripep ophthalmic solution

    Drug: 0.005% Lacripep

  • Experimental
    0.01% Lacripep

    0.01% Lacripep ophthalmic solution

    Drug: 0.01% Lacripep

  • Placebo comparator
    placebo

    placebo solution

    Drug: Placebo

Interventions

  • Drug0.005% Lacripep

    One drop (approximately 50 microliters) of 0.005% ophthalmic solution will be administered three times a day (TID) to both eyes for four weeks.

  • Drug0.01% Lacripep

    One drop (approximately 50 microliters) of 0.01% ophthalmic solution will be administered three times a day (TID) to both eyes for four weeks.

  • DrugPlacebo

    One drop (approximately 50 microliters) of placebo solution will be administered three times a day (TID) to both eyes for four weeks.

06

What researchers measure

Primary outcomes

  1. Change in Fluorescein Corneal Staining total score

    Mean change from Baseline/Randomization (Visit 2) to Day 28 (Visit 4) in Fluorescein Corneal Staining (FCS) total score \[National Eye Institute (NEI)/Industry Workshop 0-15 scale, 0-3 scale in each of 5 regions\] in the study eye.

    Time frame: Changes at Week 4 from Baseline

Secondary outcomes

  1. Eye Dryness

    Mean change from Baseline/Randomization (Visit 2) to Day 28 (Visit 4) in Eye Dryness Score (0-100 VAS scale, OU) from Individual Symptom Assessments (Instantaneous)

    Time frame: Changes at Week 4 from Baseline

  2. Mean Scores for Individual Symptom Assessments (Reflective)

    Mean Scores for six Individual Symptom Assessments (Reflective) at Day 28 (Visit 4). The individual reflective symptom assessment is assessed in 6 categories (Eye Dryness, Burning/Stinging, Foreign Body Sensation, Eye Discomfort, Eye Pain and Fluctuating Vision). An anchor in the middle at 50 mm representing their symptom severity at the last visit. The 50 mm scale to the left of the anchor located in the center of the scale will measure worsening symptoms (a negative value) and the 50 mm scale to the right of the anchor located in the center of the scale will measure improving symptoms (a positive value). The lower score represents greater severity.

    Time frame: Day 28

  3. Changes in SANDE-1 to Visit 4

    Changes in Symptom Assessment in Dry Eye Questionnaires (SANDE) Version 1 global score from Randomization/Baseline (Visit 2) to Day 28 (Visit 4). SANDE Version 1 questionnaire contains two items measuring the frequency and severity of dry eye symptoms. Each item is assessed on a 100 mm visual analog scale from 0 (Rarely for frequency, Very mild for severity) to 100 mm (All the time for frequency, Very Severe for severity), with higher scores representing greater frequency/severity.

    Time frame: Changes from Baseline to Day 28.

  4. Mean Scores SANDE 2

    Mean Scores for Symptom Assessment in Dry Eye Questionnaires (SANDE) Version 2 global scores at day 28 (Visit 4). SANDE Version 2 questionnaire contains two items measuring the frequency and severity of dry eye symptoms.The 50 mm scale to the left of the anchor located in the center of the scale will measure improving symptoms (a negative value) and the 50 mm scale to the right of the anchor located in the center of the scale will measure worsening symptoms (a positive value).

    Time frame: Day 28

  5. Changes in Individual Symptom Assessments (Instantaneous)

    Changes in each of the 5 additional Individual Symptom Assessment (Instantaneous) from Randomization/Baseline (Visit 2) to Day 28 (Visit 4). The individual instantaneous symptom assessment is a questionnaire that uses a 0-100 mm visual analog scale to rate the severity of each ocular symptom for both eyes (OU). There are six categories (Eye Dryness, Burning/Stinging, Foreign Body Sensation, Eye Discomfort, Eye Pain and Fluctuating Vision). The higher score represents more severe symptoms.

    Time frame: Changes at Baseline to Day 28

  6. Changes in LGCS

    Changes in Lissamine Green Conjunctival Staining (LGCS) from Randomization/Baseline (Visit 2) to Day 28 (Visit 4) in the study eye.

    Time frame: Changes at Week 4 from Baseline

  7. Changes in Anesthetized Schirmer test

    Change in Anesthetized Schirmer test from Randomization/Baseline (Visit 2) to Day 28 (Visit 4) in the study eye.

    Time frame: Changes at Week 4 from Baseline

  8. Changes in Tear Film Break Up Time (TFBUT)

    Changes in tear film break up time (TFBUT) from Randomization/Baseline (Visit 2) to Day 28 (Visit 4) in the study eye

    Time frame: Changes at Week 4 from Baseline

  9. Changes in FCS at Post-Treatment

    Changes in Fluorescein Corneal Staining (FCS) from Randomization/Baseline (Visit 2) to the Post-Treatment Follow-Up Visit (day 42) in the study eye. The FCS assessment will be performed for each of the five sections (Central, Inferior, Superior, Temporal, and Nasal) on both eyes (study eye and fellow eye) using the National Eye Institute (NEI)/Industry Workshop scale. The staining in each of the 5 sections of the cornea is evaluated per the NEI score: Grades of 0, 1, 2, and 3 with higher grades representing greater severity.

    Time frame: Baseline to Visit 5 / Day 42

  10. Changes in SANDE-1 to Visit 5

    Changes in Symptom Assessment in Dry Eye Questionnaires (SANDE) Version 1 global score from Randomization/Baseline (Visit 2) to the Post Treatment Follow-up visit (Day 42). SANDE Version 1 questionnaire contains two items measuring the frequency and severity of dry eye symptoms. Each item is assessed on a 100 mm visual analog scale from 0 (Rarely for frequency, Very mild for severity) to 100 mm (All the time for frequency, Very Severe for severity), with higher scores representing greater frequency/severity.

    Time frame: Baseline to Visit 5 / Day 42

  11. Changes in Individual Symptom Assessments (Instantaneous) from Baseline Visit 5

    Changes in six Individual Symptoms (Instantaneous) from Randomization/Baseline (Visit 2) to the Post-Treatment Follow-up Visit (Day 42). The individual instantaneous symptom assessment is a questionnaire that uses a 0-100 mm visual analog scale to rate the severity of each ocular symptom. There are six categories (Eye Dryness, Burning/Stinging, Foreign Body Sensation, Eye Discomfort, Eye Pain and Fluctuating Vision). The higher score represents more severe symptoms.

    Time frame: Baseline to Visit 5

  12. Mean Scores for SANDE-2

    Mean Scores for Symptom Assessment in Dry Eye Questionnaires (SANDE) Version 2 global score at the Post-Treatment Follow-Up Visit (Day 42). SANDE Version 2 questionnaire contains two items measuring the frequency and severity of dry eye symptoms.The 50 mm scale to the left of the anchor located in the center of the scale will measure improving symptoms (a negative value) and the 50 mm scale to the right of the anchor located in the center of the scale will measure worsening symptoms (a positive value).

    Time frame: Visit 5 / Day 42

  13. Mean Scores for six Individual Symptom Assessments (Reflective)

    Mean Scores for six Individual Symptom Assessments (Reflective) at the Post-Treatment Follow-Up Visit (Day 42). The individual reflective symptom assessment is assessed in 6 categories (Eye Dryness, Burning/Stinging, Foreign Body Sensation, Eye Discomfort, Eye Pain and Fluctuating Vision). The 50 mm scale to the left of the anchor located in the center of the scale will measure worsening symptoms (a negative value) and the 50 mm scale to the right of the anchor located in the center of the scale will measure improving symptoms (a positive value).

    Time frame: Visit 5 / Day 42

  14. Changes in FCS

    Mean change from Baseline/Randomization (Visit 2) to Day 28 (Visit 4) in Fluorescein Corneal Staining (FCS) total score \[National Eye Institute (NEI)/Industry Workshop 0-15 scale, 0-3 scale in each of 5 regions\] in the qualifying fellow eye.

    Time frame: Baseline to Day 28

  15. Changes in LCGS Anesthetized Schirmer test, TFBUT

    Changes in Lissamine Green Conjunctival Staining (LCGS) Anesthetized Schirmer test, tear film break up time (TFBUT) from Randomization/Baseline (Visit 2) to Day 28 (Visit 4) in the qualifying fellow eye.

    Time frame: Baseline to Day 28

07

Study locations

35 sites
  • University of Alabama Eye Center
    Birmingham, Alabama 35294, United States
  • Doctor My Eyes / Stephen Cohen, OD, PC
    Scottsdale, Arizona 85254, United States
  • Schwartz Laser Eye Center
    Scottsdale, Arizona 85260, United States
  • Milton M. Hom, OD FAAO FACAA (Sc)
    Azusa, California 91702, United States
  • University of California, Berkeley, School of Optometry
    Berkeley, California 94720, United States
  • Orange County Ophthalmology
    Garden Grove, California 92843, United States
  • Lugene Eye Institute
    Glendale, California 91204, United States
  • Martel Eye Medical Group
    Rancho Cordova, California 95670, United States
  • Wolstan & Goldberg Eye Associates
    Torrance, California 90505, United States
  • University of Colorado Department of Ophthalmology
    Aurora, Colorado 80045, United States
  • Corneal Consultants of Colorado
    Littleton, Colorado 80209, United States
  • Bruce A. Segal, MD PA Private Practice
    Delray Beach, Florida 33484, United States
  • Bowden Eye & Associates
    Jacksonville, Florida 32256, United States
  • International Eye Associates, PA
    Ormond Beach, Florida 32174, United States
  • Perez Eye Center
    Tampa, Florida 33603, United States
  • Eye Consultants of Atlanta
    Atlanta, Georgia 30339, United States
  • Chicago Cornea Consultants, Ltd.
    Hoffman Estates, Illinois 60169, United States
  • Midwest Cornea Associates, LLC
    Indianapolis, Indiana 46290, United States
  • The Eye Care Institute
    Louisville, Kentucky 40206, United States
  • Clinical Eye Research of Boston
    Winchester, Massachusetts 01890, United States
  • Minnesota Eye Consultants, P.A.
    Bloomington, Minnesota 55431, United States
  • Tauber Eye Center
    Kansas City, Missouri 64111, United States
  • Ophthalmology Associates
    Saint Louis, Missouri 63131, United States
  • Cornea Consultants of Albany
    Slingerlands, New York 12159, United States
  • Cornerstone Eye Care, PA
    High Point, North Carolina 27262, United States
  • Bergstrom Eye Research
    Fargo, North Dakota 58103, United States
  • Abrams Eye Center
    Cleveland, Ohio 44115, United States
  • Ophthalmic Surgeons & Consultants of Ohio; The Eye Center of Columbus
    Columbus, Ohio 43215, United States
  • University of Pennsylvania Scheie Eye Institute
    Philadelphia, Pennsylvania 19104, United States
  • Black Hills Eye Institute
    Rapid City, South Dakota 57701, United States
  • UTHSC Department of Ophthalmology
    Memphis, Tennessee 38163, United States
  • The Eye Clinic of Texas, an affiliate of Houston Eye Associates
    League City, Texas 77573, United States
  • University of Virginia University Eye Center
    Charlottesville, Virginia 22903, United States
  • Virginia Eye Consultants
    Norfolk, Virginia 23502, United States
  • Vistar Eye Center
    Roanoke, Virginia 24011, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2017 to primary completion in Dec 2019, 29 months.

Of 21 phase 1/2 interventional studies under Dry Eye Syndromes, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 24. This study's 29 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 19, 2017
First posted
Jul 21, 2017
StartActual
Jun 30, 2017
Primary completionActual
Dec 27, 2019
CompletionActual
Dec 27, 2019
Last update
Jan 22, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03226444
Lead sponsor
TearSolutions, Inc.
Responsible party
Sponsor
First posted
Jul 21, 2017
Start date
Jun 30, 2017
Primary completion
Dec 27, 2019
Completion
Dec 27, 2019
Last update
Jan 22, 2020

Study contacts

Marc Odrich, MD
study director · TearSolutions, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion